Phase 2 randomised non-comparative trial in 92 patients with relapsed/refractory follicular lymphoma, stopped early for slow accrual: CR at end of induction 11.4% with lenalidomide-rituximab vs 15.2% with added bendamustine; severe toxicity 6.8% vs 13.0%.
RCTn = 92
Kersten et al. Lenalidomide-rituximab or lenalidomide-rituximabbendamustine for relapsed/refractory follicular lymphoma: primary and final analysis of the randomized phase II HOVON110/ReBeL study